Treatment-free remission after stopping second-line dasatinib
Mené au Japon sur 63 patients atteints d'une leucémie myéloïde chronique présentant une réponse moléculaire profonde, cet essai multicentrique de phase II évalue l'efficacité et la toxicité d'une interruption du dasatinib après un an de traitement de seconde ligne (durée médiane de suivi : 20 mois)
Treatment-free remission after treatment with a tyrosine-kinase inhibitor (TKI) for chronic myeloid leukaemia is gaining increasing importance, as it offers patients freedom from treatment-related toxic effects and reduces long-term treatment costs. Several studies of imatinib discontinuation have been reported, but the Japanese Dasatinib Discontinuation (DADI) trial reported by Jun Imagawa and colleagues in The Lancet Haematology prospectively assessed discontinuation of second-line or subsequent dasatinib.
The Lancet Haematology , commentaire, 2014